EMFOZIN

TAB. EMFOZIN 10 Empagliflozin 10 mg BLISTER 10 X 10
TAB. EMFOZIN 25 Empagliflozin 25 mg BLISTER 10 X 10
TAB. EMFOZIN M 12.5 Empagliflozin 12.5 mg + Metformin 500 mg (SR) ALU-ALU 10 X 10
Category: Tag:
Send Enquiry
Introduction:

EMFOZIN-25 Tablet is a prescription medication containing 25 mg of Empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor. It is primarily used to manage type 2 diabetes mellitus, reduce the risk of cardiovascular death in patients with established cardiovascular disease, and treat heart failure and chronic kidney disease. By inhibiting SGLT2, EMFOZIN-25 promotes the excretion of glucose through urine, thereby lowering blood sugar levels.

Product Range & Benefits:
EMFOZIN-25

Composition: Empagliflozin 25 mg
Packaging: ALU-ALU, 10 x 10 Tablets
Use: EMFOZIN-25 is an SGLT2 inhibitor indicated for the management of type 2 diabetes mellitus, reduction of cardiovascular death risk, treatment of heart failure, and management of chronic kidney disease.

Key Benefits:

  • Effectively lowers HbA1c levels, improving glycemic control.

  • Reduces the risk of hospitalization for heart failure in patients with type 2 diabetes.

  • Promotes weight loss and lowers blood pressure.

  • Can be used as monotherapy or in combination with other antidiabetic agents.

  • Offers once-daily dosing for enhanced patient adherence.

Indications:

  • Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults and children aged 10 years and older.

  • Cardiovascular Risk Reduction: To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

  • Heart Failure: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.

  • Chronic Kidney Disease: To reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.

Dosage and Administration:

Adults:

  • Starting Dose: 10 mg orally once daily in the morning.

  • Maintenance Dose: May increase to 25 mg once daily if additional glycemic control is needed and the patient tolerates the medication.

Pediatric Patients (≥10 years):

  • Starting Dose: 10 mg orally once daily in the morning.

  • Maintenance Dose: May increase to 25 mg once daily if additional glycemic control is needed and the patient tolerates the medication.

Administration Tips:

  • Take EMFOZIN-25 Tablet orally once daily in the morning, with or without food.

  • Maintain adequate hydration to reduce the risk of hypotension.

  • If a dose is missed, take it as soon as possible. Do not double the next dose.

Precautions and Warnings:

  • Renal Impairment: Assess renal function before starting therapy. EMFOZIN-25 is not recommended for glycemic control in patients with an eGFR less than 30 mL/min/1.73 m².

  • Volume Depletion: Correct volume depletion before initiating therapy to reduce the risk of hypotension.

  • History of Genital Mycotic Infections: EMFOZIN-25 increases the risk of genital infections.

  • History of Urinary Tract Infections: Monitor for signs and symptoms of urinary tract infections.

  • Pancreatic Insufficiency or Alcohol Abuse: These conditions may increase the risk of ketoacidosis.

Contraindications:

  • Hypersensitivity to Empagliflozin or any component of the tablet.

  • Severe renal impairment (eGFR <30 mL/min/1.73 m²) for glycemic control.

  • Type 1 diabetes mellitus.

  • Diabetic ketoacidosis.

Drug Interactions:

  • Concomitant use with insulin or insulin secretagogues may increase the risk of hypoglycemia. Dose adjustments may be necessary.

  • Diuretics may enhance the risk of volume depletion and hypotension.

Potential Side Effects

Common Side Effects:

  • Urinary tract infections

  • Genital mycotic infections

  • Increased urination

  • Dizziness

  • Hypotension

Serious Side Effects:

  • Ketoacidosis

  • Acute kidney injury

  • Necrotizing fasciitis of the perineum (Fournier’s gangrene)

  • Hypersensitivity reactions (e.g., angioedema)

  • Hypoglycemia (especially when used with insulin or insulin secretagogues)

Conclusion:

EMFOZIN-25 Tablet is a versatile medication offering multiple benefits for patients with type 2 diabetes, heart failure, and chronic kidney disease. By understanding its proper use, potential side effects, and necessary precautions, patients can achieve optimal therapeutic outcomes. Always consult your healthcare provider for personalized medical advice.

Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.

For more such product information and similar product category Cardiac

You can also contact us  https://diabetes-cardiac.com/contact-us/

Related products